Skip to main content

Table 5 Estimated additional (+) impacts of seasonal trivalent influenza vaccination extrapolated to EU-27

From: Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

Influenza-related event

Numbers and costs averted additional (+) to currently averted events if VCR is increased to 75% (lower, upper limit)

Estimates using effectiveness values

Estimates using efficacy values

Number of events averted

Costs averted

Number of events averted

Costs averted

Cases of influenza

+1.6 million (0.85; 2.0)

-

+1.7 million (1.1; 2.1)

-

Influenza-related mortality

+9,843 (4,185; 14,831)

-

+14,342 (8,620; 17,939)

-

Influenza- related GP visits

+678,482 (424,321; 849,284)

+€20 million (13; 25)

+767,787 (543,913; 935,732)

+€23 million (16; 28)

Influenza-related hospitalization

+23,792 (11,199; 33,525)

+€ 57 million (28; 81)

+31,350 (19,545; 39,254)

+€75 million (47; 94)

Lost days of work

+883,750 (671,094; 1,081,253)

+€112 million (85; 137)

+1,015,145 (783,557; 1,184,489)

+€128 million (99;150)

All Influenza-related costs

-

+€190 million (125; 243)

-

+€226 million (162;272)